Lupin gets approval from Health Canada for hypertension drugs
Pharma major Lupin on Friday announced that it has received approval for its Propranolol Hydrochloride extended-release (ER) capsules in 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. The capsules will be used for the treatment of hypertension and prophylaxis of angina pectoris.
Lupin is the first generic company to receive an approval of Pfizer Canada ULCís Generic Inderal-LA capsules, the company said in a statement.The product will be manufactured from Lupinís Pithampur unit-2 facility.
As per IQVIA MAT December 2018 data, Propranolol Hydrochloride ER capsules had an annual sales of approximately CAD 8.6 million, the company said.